Grifols (NASDAQ: GRFS - Get Free Report) and Creative Medical Technology (NASDAQ: CELZ - Get Free Re

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and

Spanish drugmaker Grifols said Health Canada's decision to suspend its license to collect plasma at

Grifols is shifting to regional plasma sourcing, aiming for durable cash generation over headline ca

Gilead Sciences (NASDAQ: GILD - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) are bo

Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Gr

The portfolio's return was 5.34% (net) for the reporting period. We initiated the following position

BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a glo

Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript

Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicine

Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plas

BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a glo

First-quarter results were broadly in line with expectations, supported by strong growth in the Biop

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a glo

Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

https://www.grifols.com/en/view-news/-/news/grifols-increases-q1-2026-revenues-by-3-3-to-1-7billion-

Aldeyra Therapeutics (NASDAQ: ALDX - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) a

U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market

https://www.bloomberg.com/news/articles/2026-04-02/grifols-canadian-license-restricted-after-plasma-

OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada

Healthcare ​company Grifols ‌said ​on ​Tuesday it ⁠has ​approved ​a U.S. ​initial ​public offering o

Chronos‑PD shows that biological changes associated with Parkinson's disease (PD) can emerge up

BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a gl

TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press

https://www.grifols.com/en/view-news/-/news/grifols-reports-revenues-of-eur-7524m-up-7-and-more-than

CORRECTION: JP Morgan analyst Richard Vosser maintains Grifols (NASDAQ:GRFS) with a Neutral and main

JP Morgan analyst James Gordon maintains Grifols (NASDAQ:GRFS) with a Neutral and lowers the pric

JP Morgan analyst James Gordon maintains Grifols (NASDAQ:GRFS) with a Neutral and raises the pric

https://www.cnmv.es/webservices/verdocumento/ver?t=%7Bb75ee6db-df80-49ee-bf19-dfb0c0eed666%7D

https://www.grifols.com/en/view-news/-/news/thomas-glanzmann-to-retire-as-grifols-chairman-and-will-

https://www.bloomberg.com/news/articles/2024-12-02/grifols-shareholder-mason-capital-calls-for-board

Grifols ends acquisition talks with Brookfield over valuation concerns, highlights strong revenue gr

https://www.bloomberg.com/news/articles/2024-11-19/grifols-board-issues-unfavorable-opinion-on-brook

https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-dea

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effec

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six

Brookfield Asset Management is reportedly pursuing €9.5 billion in debt financing for a potential ta

GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally c